IGM Biosciences, Inc.

DB:1K0 Stock Report

Market Cap: €587.7m

IGM Biosciences Valuation

Is 1K0 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Book vs Peers

  • Price-To-Book vs Industry

  • Price-To-Book vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 1K0 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate 1K0's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate 1K0's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 1K0?

Key metric: As 1K0 barely has revenue we use its Price-To-Book Ratio for relative valuation analysis.

The above table shows the Price to Book ratio for 1K0. This is calculated by dividing 1K0's market cap by their current book value.
What is 1K0's PB Ratio?
PB Ratio7.9x
BookUS$78.95m
Market CapUS$620.21m

Price to Book Ratio vs Peers

How does 1K0's PB Ratio compare to its peers?

The above table shows the PB ratio for 1K0 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PBEstimated GrowthMarket Cap
Peer Average1.9x
FYB Formycon
1.5x32.4%€882.8m
2INV 2invest
1xn/a€64.4m
BIO3 Biotest
2x29.3%€1.3b
HPHA Heidelberg Pharma
3.1x-33.0%€110.9m
1K0 IGM Biosciences
7.9x3.0%€620.2m

Price-To-Book vs Peers: 1K0 is expensive based on its Price-To-Book Ratio (7.9x) compared to the peer average (1.9x).

Price to Book Ratio vs Industry

How does 1K0's PB Ratio compare vs other companies in the DE Biotechs Industry?

3 CompaniesPrice / BookEstimated GrowthMarket Cap
V9Z Aceragen
0.1xn/aUS$3.12m
V9Z Aceragen
0.1xn/aUS$2.18m
O7P NeuBase Therapeutics
0.1xn/aUS$1.39m
No more companies available in this PB range
1K0 7.9xIndustry Avg. 2.4xNo. of Companies3PB00.61.21.82.43+
3 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Book vs Industry: 1K0 is expensive based on its Price-To-Book Ratio (7.9x) compared to the European Biotechs industry average (2.4x).

Price to Book Ratio vs Fair Ratio

What is 1K0's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

1K0 PB Ratio vs Fair Ratio.
Fair Ratio
Current PB Ratio7.9x
Fair PB Ration/a

Price-To-Book vs Fair Ratio: Insufficient data to calculate 1K0's Price-To-Book Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst 1K0 forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Current€9.85
€18.50
+87.8%
55.7%€45.30€8.49n/a10
Nov ’25€15.20
€17.86
+17.5%
55.6%€44.18€8.28n/a10
Oct ’25€10.40
€17.25
+65.9%
56.6%€43.36€8.13n/a10
Sep ’25€9.30
€19.72
+112.0%
46.7%€43.22€10.80n/a10
Aug ’25€9.80
€19.85
+102.5%
48.2%€44.52€10.20n/a10
Jul ’25€6.30
€19.85
+215.0%
48.2%€44.52€10.20n/a10
Jun ’25€7.70
€19.85
+157.7%
48.2%€44.52€10.20n/a10
May ’25€8.85
€19.90
+124.8%
47.3%€44.21€11.05n/a10
Apr ’25€8.50
€19.90
+134.1%
47.3%€44.21€11.05n/a10
Mar ’25€11.90
€19.10
+60.5%
54.5%€44.50€6.49n/a10
Feb ’25€9.70
€17.34
+78.8%
64.0%€44.16€6.44n/a10
Jan ’25€7.90
€17.15
+117.1%
65.1%€44.03€6.42n/a10
Dec ’24€6.15
€19.00
+208.9%
55.1%€44.27€7.38n/a10
Nov ’24€3.68
€21.39
+481.2%
43.5%€45.43€10.41€15.2010
Oct ’24€7.70
€20.16
+161.8%
43.1%€43.80€10.04€10.4011
Sep ’24€6.55
€20.16
+207.7%
43.1%€43.80€10.04€9.3011
Aug ’24€9.25
€27.80
+200.5%
35.4%€44.72€15.52€9.8011
Jul ’24€8.95
€27.80
+210.6%
35.4%€44.72€15.52€6.3011
Jun ’24€10.90
€28.05
+157.3%
35.4%€45.13€15.66€7.7011
May ’24€9.75
€29.93
+206.9%
31.7%€45.85€18.34€8.8511
Apr ’24€13.80
€33.02
+139.3%
27.5%€46.10€18.44€8.5011
Mar ’24€19.50
€36.24
+85.9%
27.8%€53.53€22.15€11.9011
Feb ’24€21.00
€36.24
+72.6%
27.8%€53.53€22.15€9.7011
Jan ’24€15.10
€39.05
+158.6%
28.6%€57.94€21.98€7.9011
Dec ’23€20.40
€39.05
+91.4%
28.6%€57.94€21.98€6.1511
Nov ’23€20.20
€41.60
+105.9%
30.4%€61.89€27.39€3.6811

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.

Discover undervalued companies

Aspen Pharmacare Holdings

R73.7b

Manufactures and supplies specialty and branded pharmaceutical products worldwide.

LDZA

R8.60

7D

-3.9%

1Y

-0.6%

Collegium Pharmaceutical

US$990.4m

A specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management.

354

US$29.00

7D

1.4%

1Y

25.0%

Pharming Group

€492.8m

A biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally.

PHGN

€0.72

7D

-1.0%

1Y

-31.3%